JAC Advance Access published online on January 16, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh092
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review
1 GR Micro Ltd., 7-9
William Road, London NW1 3ER, UK;
* Corresponding author. E-mail: i.morrissey{at}grmicro.co.uk.
This review focuses on the activity of gemifloxacin,
a new respiratory fluoroquinolone, against the two most important
bacterial pathogens associated with lower respiratory tract infections,
namely Streptococcus pneumoniae and Haemophilus
influenzae.
Keywords: fluoroquinolones, respiratory tract infections,
fluoroquinolone resistance, community-acquired pneumonia, acute
exacerbation of chronic bronchitis
Activity of gemifloxacin against Streptococcus
pneumoniae and Haemophilus influenzae
2 Public Health Research Institute, Newark, NJ, USA
![]()
CiteULike
Connotea
Del.icio.us What's this?